Earth Science Tech (OTC: ETST) recently announced fiscal year 2026 results for the year ended March 31, 2026, highlighting growth across key financial metrics as it continues to operate its diversified holdings model spanning healthcare, pharmaceuticals, telemedicine, real estate and consumer businesses. Revenue increased 8% to $35.7 million, gross profit rose 5% to $25.5 million, net income grew 11% to $3.6 million, and total assets increased 27% to $9 million. CEO Giorgio R. Saumat attributed the results to ETST’s efforts to fully integrate the patient experience across telemedicine to pharmacy to fulfillment.
To view the full article, visit https://ibn.fm/mY8eX
About Earth Science Tech Inc.
Earth Science Tech operates as a diversified holding company focused on the health and wellness sector. The company’s principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The company’s healthcare operations are supported by investments in real estate and asset management activities and a consumer products business.
The core of the company’s value proposition is the seamless integration of patient care, from consultation to fulfillment. This is achieved through the synergy of specialized subsidiaries.
To learn more, please visit www.EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
